A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this
study will be to investigate the safety and tolerability of Fluzoparib Capsule when given
orally to Chinese patients with advanced solid malignancies. In addition, the pharmacokinetic
profile, MTD (if possible) and efficacy of Fluzoparib will be investigated.